ARCA biopharma, Inc.
(NASDAQ : ABIO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading ABIO News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.98%73.430.9%$725.96m
AMGNAmgen Inc.
0.75%180.521.1%$595.42m
CELGCelgene Corporation
1.42%136.911.1%$589.99m
REGNRegeneron Pharmaceuticals, Inc.
2.57%519.802.7%$543.97m
BIIBBiogen Inc.
0.72%283.991.2%$408.37m
VRTXVertex Pharmaceuticals Incorporated
-0.28%159.241.9%$369.08m
ALXNAlexion Pharmaceuticals, Inc.
1.70%129.461.9%$285.33m
CLVSClovis Oncology, Inc.
3.91%87.1318.0%$175.72m
INCYIncyte Corporation
2.00%133.062.6%$169.83m
TSROTESARO, Inc.
3.30%128.1114.7%$169.65m
ILMNIllumina, Inc.
-0.39%173.203.5%$159.21m
EXELExelixis, Inc.
1.91%27.266.5%$156.27m
BMRNBioMarin Pharmaceutical Inc.
0.64%87.794.4%$131.89m
KITEKite Pharma, Inc.
2.56%108.1316.1%$122.70m
BLUEBluebird Bio, Inc.
0.21%97.5019.3%$117.55m

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company's business combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, GencaroTM is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.